The FDA put both peptides on its shortage list in 2022. Semaglutide is still on that list, while the FDA lifted its shortage ...
Could popular anti-obesity medications have an impact on alcohol misuse? KYW medical editor Dr. Brian McDonough has more from ...
Results from a recent survey have prompted questions about the influence of GLP-1s on the obesity rate of U.S. adults.
A recent meta-analysis of 69 clinical trials found the risk for ischemic optic neuropathy from GLP-1 therapy is too low to be ...
Two new studies identified additional benefits of medications like semaglutide—the active ingredient in Novo Nordisk's ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk for clinically important kidney and cardiovascula ...
Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...
The holidays are a time known for feasting on delicious food, but that might not be possible for people taking weight-loss drugs.
As drugs like Ozempic and Wegovy keep flying off the shelves, more and more people are taking the drug into their own hands ...
The use of GLP-1s is linked to improved inflammatory bowel disease outcomes in patients with concomitant inflammatory bowel ...
A study reveals that weight loss can lead to significant healthcare savings, with 7% savings for a 5% BMI reduction and 30% ...
The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.